Literature DB >> 19207273

Erectile dysfunction in end-stage liver disease men.

Eric Huyghe1, Nassim Kamar, Fabien Wagner, Aude-Hélène Capietto, Labib El-Kahwaji, Fabrice Muscari, Pierre Plante, Lionel Rostaing.   

Abstract

INTRODUCTION: In men, erectile dysfunction (ED) is an important issue. Data concerning ED in men with end-stage liver disease (ESLD) is limited, and the risk factors for ED in this population are still unknown. AIMS: To determine the prevalence, timescale, and risk factors for ED in ESLD patients candidates to liver transplantation.
METHODS: Patients candidates for a liver transplantation were asked to participate in a mailed survey about sexual function. Among the 123 eligible men, 98 (84%) agreed to complete the questionnaire. MAIN OUTCOME MEASURES: The quality of erection was evaluated using the five-item International Index of Erectile Function (IIEF-5) score, and satisfaction for sexuality, using the patient-baseline Treatment-Satisfaction Scale (TSS) score. Other questions also focused on patient perception of changes over time.
RESULTS: On the overall population, 28 patients (29%) were nonsexually active. Among the 70 patients who were sexually active, 52 patients (74%) had ED. Regarding the development of ED, 50% of the patients perceived that a deterioration of erectile function occurred within the six previous months. The absence of sexual activity was more frequent in hepatitis B or C patients (P = 0.02). The risk factors for ED were alcohol intake (P = 0.03), tobacco use (P = 0.03), and cardiovascular disease (P = 0.004). The significant risk factors for having a low TSS score were having viral hepatitis (P = 0.01), and cardiovascular disease (P = 0.01).
CONCLUSION: Population of men with ESLD who are candidates for a liver transplantation is characterized by a high frequency of lack of sexual activity, and by a high prevalence of ED and should be targeted by interventions to improve sexual functioning. These preliminary data need further validation in prospective trial using more comprehensive questionnaires.

Entities:  

Mesh:

Year:  2009        PMID: 19207273     DOI: 10.1111/j.1743-6109.2008.01169.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  16 in total

1.  Sexual quality of life is impaired in patients with chronic hepatitis C.

Authors:  J Vergniol; S Duc; G Hou; J B Hiriart; J Foucher; F Chenus; C Fabères; F Chermak; A Lafournière; N Souakri; V de Lédinghen
Journal:  Int J Impot Res       Date:  2016-02-11       Impact factor: 2.896

Review 2.  Male sexual disturbances in liver diseases: what do we know?

Authors:  M Durazzo; A Premoli; C Di Bisceglie; S Bo; E Ghigo; C Manieri
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

3.  Lower urinary tract symptoms in patients with liver cirrhosis.

Authors:  Markus Margreiter; Birgit B Heinisch; Remy Schwarzer; Tobias Klatte; Shahrokh F Shariat; Arnulf Ferlitsch
Journal:  World J Urol       Date:  2014-05-06       Impact factor: 4.226

4.  Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis.

Authors:  Hye Jin Yoo; Bora Lee; Eun-Ae Jung; Sang Gyune Kim; Young Seok Kim; Jeong-Ju Yoo
Journal:  Hepatol Int       Date:  2021-11-20       Impact factor: 6.047

5.  Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot Study.

Authors:  Alok Kumar; Vivek Saraswat; Gaurav Pande; Rajesh Kumar
Journal:  J Clin Exp Hepatol       Date:  2022-01-23

6.  Erectile Dysfunction in Cirrhosis: Its Prevalence and Risk Factors.

Authors:  Rakesh K Jagdish; Ahmed Kamaal; Saggere M Shasthry; Jaya Benjamin; Rakhi Maiwall; Ankur Jindal; Ashok Choudhary; Vijayaraghavan Rajan; Vinod Arora; Ankit Bhardwaj; Guresh Kumar; Manoj Kumar; Shiv K Sarin
Journal:  J Clin Exp Hepatol       Date:  2022-05-10

Review 7.  Systemic abnormalities in liver disease.

Authors:  Masami Minemura; Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

8.  Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.

Authors:  Jitender Thakur; Sahaj Rathi; Sandeep Grover; Madhu Chopra; Swastik Agrawal; Sunil Taneja; Ajay Duseja; Anil Bhansali; Yogesh K Chawla; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2018-08-18

Review 9.  [Urological aspects in patients with liver cirrhosis].

Authors:  A Friedl; R Schwarzer; J Schneeweiss; C Brössner
Journal:  Urologe A       Date:  2016-01       Impact factor: 0.639

10.  Erectile Dysfunction in Patients with Sleep Apnea--A Nationwide Population-Based Study.

Authors:  Chia-Min Chen; Ming-Ju Tsai; Po-Ju Wei; Yu-Chung Su; Chih-Jen Yang; Meng-Ni Wu; Chung-Yao Hsu; Shang-Jyh Hwang; Inn-Wen Chong; Ming-Shyan Huang
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.